Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

5.7K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

506
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
506
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

6.8K
GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
6.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

631
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SpaceExpander: An Automated System for Drafting Markush Claims to Expand Chemical Space.

Molecular informatics·2026
Same author

Discovery of 1,2-Diol TRPV4 Antagonists with Efficacy in a 3D Myocardial Fibrosis Organoid Model and a Murine TAC Pressure-Overload Model.

Journal of medicinal chemistry·2026
Same author

Rational Design, Synthesis, and Biological Evaluation of Potent, Highly Selective 1,2,4-Oxadiazole-Based S1PR1 Agonists for UC Treatment.

Journal of medicinal chemistry·2026
Same author

mRNASyner: An Integrative Framework for Full-Length mRNA Sequence Optimization via Multimodule Synergistic Design.

Molecular pharmaceutics·2026
Same author

Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and Drugging Pockets.

JACS Au·2026
Same author

Deletion of RhoGDI Protects Against Hepatic Steatosis via Improved Mitochondrial Metabolism in Mice.

International journal of molecular sciences·2026
Same journal

Proteogenomics of Hypertrophic Cardiomyopathy Reveals Subtype-Specific Therapy.

Circulation research·2026
Same journal

Impaired Endothelial Cell Cholesterol Metabolism Promotes Vascular Inflammation in Sleep Apnea.

Circulation research·2026
Same journal

Engineered Heart Tissues Facilitate Noncoding Variant Studies in Cardiomyopathy.

Circulation research·2026
Same journal

NUAK1 Inhibition Alleviates Ischemia-Reperfusion Injury via SYNE1-YAP1.

Circulation research·2026
Same journal

Aging Disrupts L-type Ca<sup>2+</sup> Channel Organization and Function in Pacemaker Cells.

Circulation research·2026
Same journal

Glycine Receptor α2 Mediates Vasodilation via Endothelial eNOS Signaling.

Circulation research·2026
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.6K

Inhibiting RhoA Activation Via GDP-State Stabilization to Relieve Heart Failure.

Mengzhu Xue1, Yingquan Liang1, Zhen Yuan2

  • 1Innovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai, China (M.X., Y.L., L.C., Yongzhi Wang, P.X., T.Z., H.L.).

Circulation Research
|March 20, 2026
PubMed
Summary
This summary is machine-generated.

Researchers identified a novel way to target RhoA (Ras homolog gene family member A) in heart failure (HF). A natural compound, AH001, inhibits RhoA, reducing pathological remodeling and offering a new therapeutic strategy for HF patients.

Keywords:
drug therapyfibrosisheart failurehypertrophymultiomics

More Related Videos

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

10.4K
Affinity Precipitation of Active Rho-GEFs Using a GST-tagged Mutant Rho Protein GST-RhoAG17A from Epithelial Cell Lysates
11:28

Affinity Precipitation of Active Rho-GEFs Using a GST-tagged Mutant Rho Protein GST-RhoAG17A from Epithelial Cell Lysates

Published on: March 31, 2012

17.0K

Related Experiment Videos

Last Updated: Mar 21, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.6K
Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

10.4K
Affinity Precipitation of Active Rho-GEFs Using a GST-tagged Mutant Rho Protein GST-RhoAG17A from Epithelial Cell Lysates
11:28

Affinity Precipitation of Active Rho-GEFs Using a GST-tagged Mutant Rho Protein GST-RhoAG17A from Epithelial Cell Lysates

Published on: March 31, 2012

17.0K

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Pharmacology

Background:

  • Heart failure (HF) remains a leading cause of morbidity and mortality, necessitating novel therapeutic targets for myocardial remodeling.
  • Pathological hypertrophy and fibrosis are key contributors to HF progression.
  • RhoA (Ras homolog gene family member A), a regulator of cytoskeletal dynamics, is implicated in myocardial remodeling but has been considered undruggable due to its binding characteristics.

Purpose of the Study:

  • To identify and characterize a novel inhibitor of RhoA activation.
  • To validate the therapeutic potential of inhibiting RhoA in preclinical models of heart failure.
  • To establish a framework for targeting previously undruggable small GTPases.

Main Methods:

  • Utilized structural analyses and screening to identify a RhoA inhibitor (AH001).
  • Validated the inhibitory mechanism in cell cultures and 3D myocardial models.
  • Assessed therapeutic efficacy in multiple HF animal models and human heart specimens.

Main Results:

  • Discovered a cryptic pocket in RhoA that binds the natural product AH001, stabilizing RhoA inhibition by RhoGDIα.
  • AH001 suppressed downstream signaling, reducing MRTFA nuclear translocation and key proteins involved in fibrosis and hypertrophy.
  • AH001 attenuated myocardial remodeling in various HF models and 3D tissue models, disrupting pathological crosstalk.

Conclusions:

  • Pharmacological inhibition of RhoA activation is a viable strategy for mitigating myocardial remodeling in HF.
  • This study provides a conceptual framework for developing inhibitors against previously undruggable small GTPases.
  • AH001 demonstrates significant potential as a therapeutic agent for heart failure.